nodes	percent_of_prediction	percent_of_DWPC	metapath
Ceftaroline fosamil—Infestation NOS—Fluorouracil—urinary bladder cancer	0.00517	0.00517	CcSEcCtD
Ceftaroline fosamil—Infestation—Fluorouracil—urinary bladder cancer	0.00517	0.00517	CcSEcCtD
Ceftaroline fosamil—Renal failure—Gemcitabine—urinary bladder cancer	0.00517	0.00517	CcSEcCtD
Ceftaroline fosamil—Angiopathy—Thiotepa—urinary bladder cancer	0.00509	0.00509	CcSEcCtD
Ceftaroline fosamil—Immune system disorder—Thiotepa—urinary bladder cancer	0.00507	0.00507	CcSEcCtD
Ceftaroline fosamil—Vomiting—Mitomycin—urinary bladder cancer	0.00504	0.00504	CcSEcCtD
Ceftaroline fosamil—Rash—Mitomycin—urinary bladder cancer	0.005	0.005	CcSEcCtD
Ceftaroline fosamil—Dermatitis—Mitomycin—urinary bladder cancer	0.00499	0.00499	CcSEcCtD
Ceftaroline fosamil—Hepatobiliary disease—Gemcitabine—urinary bladder cancer	0.00497	0.00497	CcSEcCtD
Ceftaroline fosamil—Headache—Mitomycin—urinary bladder cancer	0.00497	0.00497	CcSEcCtD
Ceftaroline fosamil—Malnutrition—Thiotepa—urinary bladder cancer	0.00489	0.00489	CcSEcCtD
Ceftaroline fosamil—Erythema—Thiotepa—urinary bladder cancer	0.00489	0.00489	CcSEcCtD
Ceftaroline fosamil—Renal failure—Cisplatin—urinary bladder cancer	0.00482	0.00482	CcSEcCtD
Ceftaroline fosamil—Neutropenia—Etoposide—urinary bladder cancer	0.00471	0.00471	CcSEcCtD
Ceftaroline fosamil—Nausea—Mitomycin—urinary bladder cancer	0.00471	0.00471	CcSEcCtD
Ceftaroline fosamil—Urinary tract disorder—Gemcitabine—urinary bladder cancer	0.00466	0.00466	CcSEcCtD
Ceftaroline fosamil—Hepatobiliary disease—Cisplatin—urinary bladder cancer	0.00464	0.00464	CcSEcCtD
Ceftaroline fosamil—Urethral disorder—Gemcitabine—urinary bladder cancer	0.00463	0.00463	CcSEcCtD
Ceftaroline fosamil—Anaemia—Thiotepa—urinary bladder cancer	0.00452	0.00452	CcSEcCtD
Ceftaroline fosamil—Infestation NOS—Etoposide—urinary bladder cancer	0.00449	0.00449	CcSEcCtD
Ceftaroline fosamil—Infestation—Etoposide—urinary bladder cancer	0.00449	0.00449	CcSEcCtD
Ceftaroline fosamil—Bradycardia—Cisplatin—urinary bladder cancer	0.00448	0.00448	CcSEcCtD
Ceftaroline fosamil—Hyperkalaemia—Epirubicin—urinary bladder cancer	0.00442	0.00442	CcSEcCtD
Ceftaroline fosamil—Renal failure—Etoposide—urinary bladder cancer	0.00441	0.00441	CcSEcCtD
Ceftaroline fosamil—Urinary tract disorder—Cisplatin—urinary bladder cancer	0.00435	0.00435	CcSEcCtD
Ceftaroline fosamil—Urethral disorder—Cisplatin—urinary bladder cancer	0.00431	0.00431	CcSEcCtD
Ceftaroline fosamil—Angiopathy—Gemcitabine—urinary bladder cancer	0.00428	0.00428	CcSEcCtD
Ceftaroline fosamil—Immune system disorder—Gemcitabine—urinary bladder cancer	0.00426	0.00426	CcSEcCtD
Ceftaroline fosamil—Hepatobiliary disease—Etoposide—urinary bladder cancer	0.00425	0.00425	CcSEcCtD
Ceftaroline fosamil—Convulsion—Thiotepa—urinary bladder cancer	0.00423	0.00423	CcSEcCtD
Ceftaroline fosamil—Unspecified disorder of skin and subcutaneous tissue—Thiotepa—urinary bladder cancer	0.00413	0.00413	CcSEcCtD
Ceftaroline fosamil—Erythema—Gemcitabine—urinary bladder cancer	0.00411	0.00411	CcSEcCtD
Ceftaroline fosamil—Hyperkalaemia—Doxorubicin—urinary bladder cancer	0.00409	0.00409	CcSEcCtD
Ceftaroline fosamil—Erythema—Fluorouracil—urinary bladder cancer	0.00404	0.00404	CcSEcCtD
Ceftaroline fosamil—Urinary tract disorder—Etoposide—urinary bladder cancer	0.00398	0.00398	CcSEcCtD
Ceftaroline fosamil—Immune system disorder—Cisplatin—urinary bladder cancer	0.00397	0.00397	CcSEcCtD
Ceftaroline fosamil—Urethral disorder—Etoposide—urinary bladder cancer	0.00395	0.00395	CcSEcCtD
Ceftaroline fosamil—Nervous system disorder—Thiotepa—urinary bladder cancer	0.00391	0.00391	CcSEcCtD
Ceftaroline fosamil—Thrombocytopenia—Thiotepa—urinary bladder cancer	0.0039	0.0039	CcSEcCtD
Ceftaroline fosamil—Skin disorder—Thiotepa—urinary bladder cancer	0.00387	0.00387	CcSEcCtD
Ceftaroline fosamil—Erythema—Cisplatin—urinary bladder cancer	0.00383	0.00383	CcSEcCtD
Ceftaroline fosamil—Malnutrition—Cisplatin—urinary bladder cancer	0.00383	0.00383	CcSEcCtD
Ceftaroline fosamil—Anaemia—Gemcitabine—urinary bladder cancer	0.0038	0.0038	CcSEcCtD
Ceftaroline fosamil—Phlebitis—Epirubicin—urinary bladder cancer	0.00379	0.00379	CcSEcCtD
Ceftaroline fosamil—Anaemia—Fluorouracil—urinary bladder cancer	0.00373	0.00373	CcSEcCtD
Ceftaroline fosamil—Angiopathy—Etoposide—urinary bladder cancer	0.00366	0.00366	CcSEcCtD
Ceftaroline fosamil—Immune system disorder—Etoposide—urinary bladder cancer	0.00364	0.00364	CcSEcCtD
Ceftaroline fosamil—Anaemia—Cisplatin—urinary bladder cancer	0.00354	0.00354	CcSEcCtD
Ceftaroline fosamil—Phlebitis—Doxorubicin—urinary bladder cancer	0.00351	0.00351	CcSEcCtD
Ceftaroline fosamil—Convulsion—Fluorouracil—urinary bladder cancer	0.0035	0.0035	CcSEcCtD
Ceftaroline fosamil—Unspecified disorder of skin and subcutaneous tissue—Gemcitabine—urinary bladder cancer	0.00347	0.00347	CcSEcCtD
Ceftaroline fosamil—Gastrointestinal disorder—Thiotepa—urinary bladder cancer	0.00344	0.00344	CcSEcCtD
Ceftaroline fosamil—Pain—Thiotepa—urinary bladder cancer	0.00341	0.00341	CcSEcCtD
Ceftaroline fosamil—Constipation—Thiotepa—urinary bladder cancer	0.00341	0.00341	CcSEcCtD
Ceftaroline fosamil—Anaphylactic shock—Gemcitabine—urinary bladder cancer	0.00335	0.00335	CcSEcCtD
Ceftaroline fosamil—Convulsion—Cisplatin—urinary bladder cancer	0.00332	0.00332	CcSEcCtD
Ceftaroline fosamil—Anaphylactic shock—Fluorouracil—urinary bladder cancer	0.0033	0.0033	CcSEcCtD
Ceftaroline fosamil—Nervous system disorder—Gemcitabine—urinary bladder cancer	0.00329	0.00329	CcSEcCtD
Ceftaroline fosamil—Thrombocytopenia—Gemcitabine—urinary bladder cancer	0.00328	0.00328	CcSEcCtD
Ceftaroline fosamil—Gastrointestinal pain—Thiotepa—urinary bladder cancer	0.00326	0.00326	CcSEcCtD
Ceftaroline fosamil—Skin disorder—Gemcitabine—urinary bladder cancer	0.00326	0.00326	CcSEcCtD
Ceftaroline fosamil—Anaemia—Etoposide—urinary bladder cancer	0.00324	0.00324	CcSEcCtD
Ceftaroline fosamil—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—urinary bladder cancer	0.00324	0.00324	CcSEcCtD
Ceftaroline fosamil—Nervous system disorder—Fluorouracil—urinary bladder cancer	0.00323	0.00323	CcSEcCtD
Ceftaroline fosamil—Thrombocytopenia—Fluorouracil—urinary bladder cancer	0.00323	0.00323	CcSEcCtD
Ceftaroline fosamil—Urticaria—Thiotepa—urinary bladder cancer	0.00317	0.00317	CcSEcCtD
Ceftaroline fosamil—Body temperature increased—Thiotepa—urinary bladder cancer	0.00315	0.00315	CcSEcCtD
Ceftaroline fosamil—Abdominal pain—Thiotepa—urinary bladder cancer	0.00315	0.00315	CcSEcCtD
Ceftaroline fosamil—Anaphylactic shock—Cisplatin—urinary bladder cancer	0.00313	0.00313	CcSEcCtD
Ceftaroline fosamil—Nervous system disorder—Cisplatin—urinary bladder cancer	0.00307	0.00307	CcSEcCtD
Ceftaroline fosamil—Thrombocytopenia—Cisplatin—urinary bladder cancer	0.00306	0.00306	CcSEcCtD
Ceftaroline fosamil—Convulsion—Etoposide—urinary bladder cancer	0.00304	0.00304	CcSEcCtD
Ceftaroline fosamil—Skin disorder—Cisplatin—urinary bladder cancer	0.00304	0.00304	CcSEcCtD
Ceftaroline fosamil—Eosinophilia—Methotrexate—urinary bladder cancer	0.00299	0.00299	CcSEcCtD
Ceftaroline fosamil—Hypokalaemia—Epirubicin—urinary bladder cancer	0.00297	0.00297	CcSEcCtD
Ceftaroline fosamil—Unspecified disorder of skin and subcutaneous tissue—Etoposide—urinary bladder cancer	0.00297	0.00297	CcSEcCtD
Ceftaroline fosamil—Hypersensitivity—Thiotepa—urinary bladder cancer	0.00294	0.00294	CcSEcCtD
Ceftaroline fosamil—Gastrointestinal disorder—Gemcitabine—urinary bladder cancer	0.0029	0.0029	CcSEcCtD
Ceftaroline fosamil—Pain—Gemcitabine—urinary bladder cancer	0.00287	0.00287	CcSEcCtD
Ceftaroline fosamil—Constipation—Gemcitabine—urinary bladder cancer	0.00287	0.00287	CcSEcCtD
Ceftaroline fosamil—Anaphylactic shock—Etoposide—urinary bladder cancer	0.00286	0.00286	CcSEcCtD
Ceftaroline fosamil—Gastrointestinal disorder—Fluorouracil—urinary bladder cancer	0.00285	0.00285	CcSEcCtD
Ceftaroline fosamil—Neutropenia—Methotrexate—urinary bladder cancer	0.00282	0.00282	CcSEcCtD
Ceftaroline fosamil—Pruritus—Thiotepa—urinary bladder cancer	0.00282	0.00282	CcSEcCtD
Ceftaroline fosamil—Pain—Fluorouracil—urinary bladder cancer	0.00282	0.00282	CcSEcCtD
Ceftaroline fosamil—Thrombocytopenia—Etoposide—urinary bladder cancer	0.0028	0.0028	CcSEcCtD
Ceftaroline fosamil—Eosinophilia—Epirubicin—urinary bladder cancer	0.0028	0.0028	CcSEcCtD
Ceftaroline fosamil—Skin disorder—Etoposide—urinary bladder cancer	0.00278	0.00278	CcSEcCtD
Ceftaroline fosamil—Hypokalaemia—Doxorubicin—urinary bladder cancer	0.00275	0.00275	CcSEcCtD
Ceftaroline fosamil—Diarrhoea—Thiotepa—urinary bladder cancer	0.00273	0.00273	CcSEcCtD
Ceftaroline fosamil—Gastrointestinal disorder—Cisplatin—urinary bladder cancer	0.0027	0.0027	CcSEcCtD
Ceftaroline fosamil—Infestation—Methotrexate—urinary bladder cancer	0.00269	0.00269	CcSEcCtD
Ceftaroline fosamil—Infestation NOS—Methotrexate—urinary bladder cancer	0.00269	0.00269	CcSEcCtD
Ceftaroline fosamil—Pain—Cisplatin—urinary bladder cancer	0.00267	0.00267	CcSEcCtD
Ceftaroline fosamil—Body temperature increased—Gemcitabine—urinary bladder cancer	0.00265	0.00265	CcSEcCtD
Ceftaroline fosamil—Renal failure—Methotrexate—urinary bladder cancer	0.00264	0.00264	CcSEcCtD
Ceftaroline fosamil—Neutropenia—Epirubicin—urinary bladder cancer	0.00264	0.00264	CcSEcCtD
Ceftaroline fosamil—Dizziness—Thiotepa—urinary bladder cancer	0.00264	0.00264	CcSEcCtD
Ceftaroline fosamil—Urticaria—Fluorouracil—urinary bladder cancer	0.00262	0.00262	CcSEcCtD
Ceftaroline fosamil—Body temperature increased—Fluorouracil—urinary bladder cancer	0.00261	0.00261	CcSEcCtD
Ceftaroline fosamil—Eosinophilia—Doxorubicin—urinary bladder cancer	0.00259	0.00259	CcSEcCtD
Ceftaroline fosamil—Hyperglycaemia—Epirubicin—urinary bladder cancer	0.00255	0.00255	CcSEcCtD
Ceftaroline fosamil—Hepatobiliary disease—Methotrexate—urinary bladder cancer	0.00254	0.00254	CcSEcCtD
Ceftaroline fosamil—Vomiting—Thiotepa—urinary bladder cancer	0.00254	0.00254	CcSEcCtD
Ceftaroline fosamil—Infestation—Epirubicin—urinary bladder cancer	0.00252	0.00252	CcSEcCtD
Ceftaroline fosamil—Infestation NOS—Epirubicin—urinary bladder cancer	0.00252	0.00252	CcSEcCtD
Ceftaroline fosamil—Rash—Thiotepa—urinary bladder cancer	0.00251	0.00251	CcSEcCtD
Ceftaroline fosamil—Dermatitis—Thiotepa—urinary bladder cancer	0.00251	0.00251	CcSEcCtD
Ceftaroline fosamil—Headache—Thiotepa—urinary bladder cancer	0.0025	0.0025	CcSEcCtD
Ceftaroline fosamil—Renal failure—Epirubicin—urinary bladder cancer	0.00247	0.00247	CcSEcCtD
Ceftaroline fosamil—Gastrointestinal disorder—Etoposide—urinary bladder cancer	0.00247	0.00247	CcSEcCtD
Ceftaroline fosamil—Body temperature increased—Cisplatin—urinary bladder cancer	0.00247	0.00247	CcSEcCtD
Ceftaroline fosamil—Pain—Etoposide—urinary bladder cancer	0.00245	0.00245	CcSEcCtD
Ceftaroline fosamil—Constipation—Etoposide—urinary bladder cancer	0.00245	0.00245	CcSEcCtD
Ceftaroline fosamil—Neutropenia—Doxorubicin—urinary bladder cancer	0.00244	0.00244	CcSEcCtD
Ceftaroline fosamil—Hypersensitivity—Fluorouracil—urinary bladder cancer	0.00243	0.00243	CcSEcCtD
Ceftaroline fosamil—Hepatitis—Methotrexate—urinary bladder cancer	0.00241	0.00241	CcSEcCtD
Ceftaroline fosamil—Urinary tract disorder—Methotrexate—urinary bladder cancer	0.00238	0.00238	CcSEcCtD
Ceftaroline fosamil—Hepatobiliary disease—Epirubicin—urinary bladder cancer	0.00238	0.00238	CcSEcCtD
Ceftaroline fosamil—Pruritus—Gemcitabine—urinary bladder cancer	0.00237	0.00237	CcSEcCtD
Ceftaroline fosamil—Nausea—Thiotepa—urinary bladder cancer	0.00237	0.00237	CcSEcCtD
Ceftaroline fosamil—Urethral disorder—Methotrexate—urinary bladder cancer	0.00237	0.00237	CcSEcCtD
Ceftaroline fosamil—Hyperglycaemia—Doxorubicin—urinary bladder cancer	0.00236	0.00236	CcSEcCtD
Ceftaroline fosamil—Gastrointestinal pain—Etoposide—urinary bladder cancer	0.00234	0.00234	CcSEcCtD
Ceftaroline fosamil—Pruritus—Fluorouracil—urinary bladder cancer	0.00233	0.00233	CcSEcCtD
Ceftaroline fosamil—Infestation NOS—Doxorubicin—urinary bladder cancer	0.00233	0.00233	CcSEcCtD
Ceftaroline fosamil—Infestation—Doxorubicin—urinary bladder cancer	0.00233	0.00233	CcSEcCtD
Ceftaroline fosamil—Hypersensitivity—Cisplatin—urinary bladder cancer	0.0023	0.0023	CcSEcCtD
Ceftaroline fosamil—Bradycardia—Epirubicin—urinary bladder cancer	0.0023	0.0023	CcSEcCtD
Ceftaroline fosamil—Diarrhoea—Gemcitabine—urinary bladder cancer	0.00229	0.00229	CcSEcCtD
Ceftaroline fosamil—Renal failure—Doxorubicin—urinary bladder cancer	0.00229	0.00229	CcSEcCtD
Ceftaroline fosamil—Urticaria—Etoposide—urinary bladder cancer	0.00228	0.00228	CcSEcCtD
Ceftaroline fosamil—Abdominal pain—Etoposide—urinary bladder cancer	0.00226	0.00226	CcSEcCtD
Ceftaroline fosamil—Body temperature increased—Etoposide—urinary bladder cancer	0.00226	0.00226	CcSEcCtD
Ceftaroline fosamil—Hepatitis—Epirubicin—urinary bladder cancer	0.00226	0.00226	CcSEcCtD
Ceftaroline fosamil—Diarrhoea—Fluorouracil—urinary bladder cancer	0.00226	0.00226	CcSEcCtD
Ceftaroline fosamil—Urinary tract disorder—Epirubicin—urinary bladder cancer	0.00223	0.00223	CcSEcCtD
Ceftaroline fosamil—Urethral disorder—Epirubicin—urinary bladder cancer	0.00222	0.00222	CcSEcCtD
Ceftaroline fosamil—Hepatobiliary disease—Doxorubicin—urinary bladder cancer	0.0022	0.0022	CcSEcCtD
Ceftaroline fosamil—Angiopathy—Methotrexate—urinary bladder cancer	0.00219	0.00219	CcSEcCtD
Ceftaroline fosamil—Immune system disorder—Methotrexate—urinary bladder cancer	0.00218	0.00218	CcSEcCtD
Ceftaroline fosamil—Dizziness—Fluorouracil—urinary bladder cancer	0.00218	0.00218	CcSEcCtD
Ceftaroline fosamil—Diarrhoea—Cisplatin—urinary bladder cancer	0.00214	0.00214	CcSEcCtD
Ceftaroline fosamil—Vomiting—Gemcitabine—urinary bladder cancer	0.00213	0.00213	CcSEcCtD
Ceftaroline fosamil—Bradycardia—Doxorubicin—urinary bladder cancer	0.00213	0.00213	CcSEcCtD
Ceftaroline fosamil—Rash—Gemcitabine—urinary bladder cancer	0.00211	0.00211	CcSEcCtD
Ceftaroline fosamil—Dermatitis—Gemcitabine—urinary bladder cancer	0.00211	0.00211	CcSEcCtD
Ceftaroline fosamil—Hypersensitivity—Etoposide—urinary bladder cancer	0.00211	0.00211	CcSEcCtD
Ceftaroline fosamil—Erythema—Methotrexate—urinary bladder cancer	0.0021	0.0021	CcSEcCtD
Ceftaroline fosamil—Malnutrition—Methotrexate—urinary bladder cancer	0.0021	0.0021	CcSEcCtD
Ceftaroline fosamil—Headache—Gemcitabine—urinary bladder cancer	0.0021	0.0021	CcSEcCtD
Ceftaroline fosamil—Vomiting—Fluorouracil—urinary bladder cancer	0.0021	0.0021	CcSEcCtD
Ceftaroline fosamil—Hepatitis—Doxorubicin—urinary bladder cancer	0.00209	0.00209	CcSEcCtD
Ceftaroline fosamil—Rash—Fluorouracil—urinary bladder cancer	0.00208	0.00208	CcSEcCtD
Ceftaroline fosamil—Dermatitis—Fluorouracil—urinary bladder cancer	0.00208	0.00208	CcSEcCtD
Ceftaroline fosamil—Headache—Fluorouracil—urinary bladder cancer	0.00207	0.00207	CcSEcCtD
Ceftaroline fosamil—Urinary tract disorder—Doxorubicin—urinary bladder cancer	0.00206	0.00206	CcSEcCtD
Ceftaroline fosamil—Angiopathy—Epirubicin—urinary bladder cancer	0.00205	0.00205	CcSEcCtD
Ceftaroline fosamil—Urethral disorder—Doxorubicin—urinary bladder cancer	0.00205	0.00205	CcSEcCtD
Ceftaroline fosamil—Immune system disorder—Epirubicin—urinary bladder cancer	0.00204	0.00204	CcSEcCtD
Ceftaroline fosamil—Pruritus—Etoposide—urinary bladder cancer	0.00203	0.00203	CcSEcCtD
Ceftaroline fosamil—Nausea—Gemcitabine—urinary bladder cancer	0.00199	0.00199	CcSEcCtD
Ceftaroline fosamil—Vomiting—Cisplatin—urinary bladder cancer	0.00199	0.00199	CcSEcCtD
Ceftaroline fosamil—Rash—Cisplatin—urinary bladder cancer	0.00197	0.00197	CcSEcCtD
Ceftaroline fosamil—Dermatitis—Cisplatin—urinary bladder cancer	0.00197	0.00197	CcSEcCtD
Ceftaroline fosamil—Erythema—Epirubicin—urinary bladder cancer	0.00197	0.00197	CcSEcCtD
Ceftaroline fosamil—Malnutrition—Epirubicin—urinary bladder cancer	0.00197	0.00197	CcSEcCtD
Ceftaroline fosamil—Diarrhoea—Etoposide—urinary bladder cancer	0.00196	0.00196	CcSEcCtD
Ceftaroline fosamil—Nausea—Fluorouracil—urinary bladder cancer	0.00196	0.00196	CcSEcCtD
Ceftaroline fosamil—Anaemia—Methotrexate—urinary bladder cancer	0.00194	0.00194	CcSEcCtD
Ceftaroline fosamil—Angiopathy—Doxorubicin—urinary bladder cancer	0.0019	0.0019	CcSEcCtD
Ceftaroline fosamil—Dizziness—Etoposide—urinary bladder cancer	0.00189	0.00189	CcSEcCtD
Ceftaroline fosamil—Immune system disorder—Doxorubicin—urinary bladder cancer	0.00189	0.00189	CcSEcCtD
Ceftaroline fosamil—Nausea—Cisplatin—urinary bladder cancer	0.00186	0.00186	CcSEcCtD
Ceftaroline fosamil—Convulsion—Methotrexate—urinary bladder cancer	0.00182	0.00182	CcSEcCtD
Ceftaroline fosamil—Vomiting—Etoposide—urinary bladder cancer	0.00182	0.00182	CcSEcCtD
Ceftaroline fosamil—Erythema—Doxorubicin—urinary bladder cancer	0.00182	0.00182	CcSEcCtD
Ceftaroline fosamil—Malnutrition—Doxorubicin—urinary bladder cancer	0.00182	0.00182	CcSEcCtD
Ceftaroline fosamil—Anaemia—Epirubicin—urinary bladder cancer	0.00182	0.00182	CcSEcCtD
Ceftaroline fosamil—Rash—Etoposide—urinary bladder cancer	0.00181	0.00181	CcSEcCtD
Ceftaroline fosamil—Dermatitis—Etoposide—urinary bladder cancer	0.0018	0.0018	CcSEcCtD
Ceftaroline fosamil—Headache—Etoposide—urinary bladder cancer	0.00179	0.00179	CcSEcCtD
Ceftaroline fosamil—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	0.00178	0.00178	CcSEcCtD
Ceftaroline fosamil—Palpitations—Epirubicin—urinary bladder cancer	0.00174	0.00174	CcSEcCtD
Ceftaroline fosamil—Anaphylactic shock—Methotrexate—urinary bladder cancer	0.00172	0.00172	CcSEcCtD
Ceftaroline fosamil—Convulsion—Epirubicin—urinary bladder cancer	0.0017	0.0017	CcSEcCtD
Ceftaroline fosamil—Nausea—Etoposide—urinary bladder cancer	0.0017	0.0017	CcSEcCtD
Ceftaroline fosamil—Nervous system disorder—Methotrexate—urinary bladder cancer	0.00168	0.00168	CcSEcCtD
Ceftaroline fosamil—Anaemia—Doxorubicin—urinary bladder cancer	0.00168	0.00168	CcSEcCtD
Ceftaroline fosamil—Thrombocytopenia—Methotrexate—urinary bladder cancer	0.00168	0.00168	CcSEcCtD
Ceftaroline fosamil—Skin disorder—Methotrexate—urinary bladder cancer	0.00167	0.00167	CcSEcCtD
Ceftaroline fosamil—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	0.00166	0.00166	CcSEcCtD
Ceftaroline fosamil—Palpitations—Doxorubicin—urinary bladder cancer	0.00161	0.00161	CcSEcCtD
Ceftaroline fosamil—Anaphylactic shock—Epirubicin—urinary bladder cancer	0.00161	0.00161	CcSEcCtD
Ceftaroline fosamil—Convulsion—Doxorubicin—urinary bladder cancer	0.00158	0.00158	CcSEcCtD
Ceftaroline fosamil—Nervous system disorder—Epirubicin—urinary bladder cancer	0.00157	0.00157	CcSEcCtD
Ceftaroline fosamil—Thrombocytopenia—Epirubicin—urinary bladder cancer	0.00157	0.00157	CcSEcCtD
Ceftaroline fosamil—Skin disorder—Epirubicin—urinary bladder cancer	0.00156	0.00156	CcSEcCtD
Ceftaroline fosamil—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	0.00154	0.00154	CcSEcCtD
Ceftaroline fosamil—Anaphylactic shock—Doxorubicin—urinary bladder cancer	0.00149	0.00149	CcSEcCtD
Ceftaroline fosamil—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	0.00148	0.00148	CcSEcCtD
Ceftaroline fosamil—Pain—Methotrexate—urinary bladder cancer	0.00147	0.00147	CcSEcCtD
Ceftaroline fosamil—Nervous system disorder—Doxorubicin—urinary bladder cancer	0.00146	0.00146	CcSEcCtD
Ceftaroline fosamil—Thrombocytopenia—Doxorubicin—urinary bladder cancer	0.00145	0.00145	CcSEcCtD
Ceftaroline fosamil—Skin disorder—Doxorubicin—urinary bladder cancer	0.00144	0.00144	CcSEcCtD
Ceftaroline fosamil—Gastrointestinal pain—Methotrexate—urinary bladder cancer	0.0014	0.0014	CcSEcCtD
Ceftaroline fosamil—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	0.00139	0.00139	CcSEcCtD
Ceftaroline fosamil—Constipation—Epirubicin—urinary bladder cancer	0.00137	0.00137	CcSEcCtD
Ceftaroline fosamil—Pain—Epirubicin—urinary bladder cancer	0.00137	0.00137	CcSEcCtD
Ceftaroline fosamil—Urticaria—Methotrexate—urinary bladder cancer	0.00136	0.00136	CcSEcCtD
Ceftaroline fosamil—Abdominal pain—Methotrexate—urinary bladder cancer	0.00136	0.00136	CcSEcCtD
Ceftaroline fosamil—Body temperature increased—Methotrexate—urinary bladder cancer	0.00136	0.00136	CcSEcCtD
Ceftaroline fosamil—Gastrointestinal pain—Epirubicin—urinary bladder cancer	0.00131	0.00131	CcSEcCtD
Ceftaroline fosamil—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	0.00128	0.00128	CcSEcCtD
Ceftaroline fosamil—Urticaria—Epirubicin—urinary bladder cancer	0.00128	0.00128	CcSEcCtD
Ceftaroline fosamil—Pain—Doxorubicin—urinary bladder cancer	0.00127	0.00127	CcSEcCtD
Ceftaroline fosamil—Constipation—Doxorubicin—urinary bladder cancer	0.00127	0.00127	CcSEcCtD
Ceftaroline fosamil—Abdominal pain—Epirubicin—urinary bladder cancer	0.00127	0.00127	CcSEcCtD
Ceftaroline fosamil—Body temperature increased—Epirubicin—urinary bladder cancer	0.00127	0.00127	CcSEcCtD
Ceftaroline fosamil—Hypersensitivity—Methotrexate—urinary bladder cancer	0.00126	0.00126	CcSEcCtD
Ceftaroline fosamil—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	0.00121	0.00121	CcSEcCtD
Ceftaroline fosamil—Pruritus—Methotrexate—urinary bladder cancer	0.00121	0.00121	CcSEcCtD
Ceftaroline fosamil—Hypersensitivity—Epirubicin—urinary bladder cancer	0.00118	0.00118	CcSEcCtD
Ceftaroline fosamil—Urticaria—Doxorubicin—urinary bladder cancer	0.00118	0.00118	CcSEcCtD
Ceftaroline fosamil—Abdominal pain—Doxorubicin—urinary bladder cancer	0.00117	0.00117	CcSEcCtD
Ceftaroline fosamil—Body temperature increased—Doxorubicin—urinary bladder cancer	0.00117	0.00117	CcSEcCtD
Ceftaroline fosamil—Diarrhoea—Methotrexate—urinary bladder cancer	0.00117	0.00117	CcSEcCtD
Ceftaroline fosamil—Pruritus—Epirubicin—urinary bladder cancer	0.00114	0.00114	CcSEcCtD
Ceftaroline fosamil—Dizziness—Methotrexate—urinary bladder cancer	0.00113	0.00113	CcSEcCtD
Ceftaroline fosamil—Diarrhoea—Epirubicin—urinary bladder cancer	0.0011	0.0011	CcSEcCtD
Ceftaroline fosamil—Hypersensitivity—Doxorubicin—urinary bladder cancer	0.00109	0.00109	CcSEcCtD
Ceftaroline fosamil—Vomiting—Methotrexate—urinary bladder cancer	0.00109	0.00109	CcSEcCtD
Ceftaroline fosamil—Rash—Methotrexate—urinary bladder cancer	0.00108	0.00108	CcSEcCtD
Ceftaroline fosamil—Dermatitis—Methotrexate—urinary bladder cancer	0.00108	0.00108	CcSEcCtD
Ceftaroline fosamil—Headache—Methotrexate—urinary bladder cancer	0.00107	0.00107	CcSEcCtD
Ceftaroline fosamil—Dizziness—Epirubicin—urinary bladder cancer	0.00106	0.00106	CcSEcCtD
Ceftaroline fosamil—Pruritus—Doxorubicin—urinary bladder cancer	0.00105	0.00105	CcSEcCtD
Ceftaroline fosamil—Vomiting—Epirubicin—urinary bladder cancer	0.00102	0.00102	CcSEcCtD
Ceftaroline fosamil—Nausea—Methotrexate—urinary bladder cancer	0.00102	0.00102	CcSEcCtD
Ceftaroline fosamil—Diarrhoea—Doxorubicin—urinary bladder cancer	0.00102	0.00102	CcSEcCtD
Ceftaroline fosamil—Rash—Epirubicin—urinary bladder cancer	0.00101	0.00101	CcSEcCtD
Ceftaroline fosamil—Dermatitis—Epirubicin—urinary bladder cancer	0.00101	0.00101	CcSEcCtD
Ceftaroline fosamil—Headache—Epirubicin—urinary bladder cancer	0.00101	0.00101	CcSEcCtD
Ceftaroline fosamil—Dizziness—Doxorubicin—urinary bladder cancer	0.000982	0.000982	CcSEcCtD
Ceftaroline fosamil—Nausea—Epirubicin—urinary bladder cancer	0.000954	0.000954	CcSEcCtD
Ceftaroline fosamil—Vomiting—Doxorubicin—urinary bladder cancer	0.000945	0.000945	CcSEcCtD
Ceftaroline fosamil—Rash—Doxorubicin—urinary bladder cancer	0.000937	0.000937	CcSEcCtD
Ceftaroline fosamil—Dermatitis—Doxorubicin—urinary bladder cancer	0.000936	0.000936	CcSEcCtD
Ceftaroline fosamil—Headache—Doxorubicin—urinary bladder cancer	0.000931	0.000931	CcSEcCtD
Ceftaroline fosamil—Nausea—Doxorubicin—urinary bladder cancer	0.000882	0.000882	CcSEcCtD
